Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model - PubMed (original) (raw)

Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model

H P Hammes et al. Diabetologia. 1995 Jun.

Abstract

Primary prevention with aminoguanidine-an inhibitor of advanced glycation end product (AGE) formation--has been successfully employed to prevent diabetic retinopathy in the rat. However, it is unknown whether inhibition of AGE formation is still effective in a secondary intervention strategy. The present study addresses this question by comparing secondary intervention with aminoguanidine with syngeneic islet transplantation in the rat model. After 6 months of diabetes, one group was treated with aminoguanidine (50 mg/100 ml drinking water; D-AG) while another group received syngeneic transplantation of collagenase-ficoll isolated islets by intraportal injection (Tx). After an additional 4 months, both groups were compared to a normal (NC 10) and diabetic (DC 10) control group. Retinal autofluorescence was increased 2.5-fold after 6 months and increased 3.7-fold after 10 months of diabetes (p < 0.001). Aminoguanidine and islet Tx retarded the further accumulation of autofluorescence equally (p < 0.001 vs DC 10), although the values were higher than those observed in DC at 6 months (p < 0.001). Diabetes was associated with a 2.7-fold increase in acellular capillaries after 6 months and a 4.1-fold increase after 10 months. Treatment with aminoguanidine or islet Tx reduced but did not completely attenuate the progression of vascular occlusion (p < 0.001 vs DC 10; D-AG vs DC 6, p < 0.05; Tx vs DC 6, p < 0.01). Both treatments reduced endothelial proliferation (22.4% after 10 months; p < 0.001) and completely arrested pericyte dropout (40% after 10 months; p < 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

PubMed Disclaimer

Similar articles

• Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats.
  Hammes HP, Ali SS, Uhlmann M, Weiss A, Federlin K, Geisen K, Brownlee M. Hammes HP, et al. Diabetologia. 1995 Mar;38(3):269-73. doi: 10.1007/BF00400629. Diabetologia. 1995. PMID: 7758871
• Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat.
  Hammes HP, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K. Hammes HP, et al. Diabetologia. 1994 Jan;37(1):32-5. doi: 10.1007/BF00428774. Diabetologia. 1994. PMID: 8150227
• Islet transplantation inhibits diabetic retinopathy in the sucrose-fed diabetic Cohen rat.
  Hammes HP, Klinzing I, Wiegand S, Bretzel RG, Cohen AM, Federlin K. Hammes HP, et al. Invest Ophthalmol Vis Sci. 1993 May;34(6):2092-6. Invest Ophthalmol Vis Sci. 1993. PMID: 8491559
• Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy.
  Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Hammes HP, et al. Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11555-8. doi: 10.1073/pnas.88.24.11555. Proc Natl Acad Sci U S A. 1991. PMID: 1763069 Free PMC article.
• Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts.
  Thornalley PJ. Thornalley PJ. Arch Biochem Biophys. 2003 Nov 1;419(1):31-40. doi: 10.1016/j.abb.2003.08.013. Arch Biochem Biophys. 2003. PMID: 14568006 Review.

Cited by

• Glyoxalase System as a Therapeutic Target against Diabetic Retinopathy.
  Aragonès G, Rowan S, G Francisco S, Yang W, Weinberg J, Taylor A, Bejarano E. Aragonès G, et al. Antioxidants (Basel). 2020 Oct 30;9(11):1062. doi: 10.3390/antiox9111062. Antioxidants (Basel). 2020. PMID: 33143048 Free PMC article. Review.
• Too sweet: Problems of protein glycation in the eye.
  Bejarano E, Taylor A. Bejarano E, et al. Exp Eye Res. 2019 Jan;178:255-262. doi: 10.1016/j.exer.2018.08.017. Epub 2018 Aug 24. Exp Eye Res. 2019. PMID: 30145354 Free PMC article. Review.
• Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis.
  Lyons TJ, Jenkins AJ. Lyons TJ, et al. Diabetes Rev (Alex). 1997;5(4):365-391. Diabetes Rev (Alex). 1997. PMID: 26366051 Free PMC article.
• Retinylamine Benefits Early Diabetic Retinopathy in Mice.
  Liu H, Tang J, Du Y, Lee CA, Golczak M, Muthusamy A, Antonetti DA, Veenstra AA, Amengual J, von Lintig J, Palczewski K, Kern TS. Liu H, et al. J Biol Chem. 2015 Aug 28;290(35):21568-79. doi: 10.1074/jbc.M115.655555. Epub 2015 Jul 2. J Biol Chem. 2015. PMID: 26139608 Free PMC article.
• Antioxidative and aldose reductase-inhibitory effects of a fermentation filtrate of Rubus coreanus.
  Kwon SC, Kim YB. Kwon SC, et al. Lab Anim Res. 2011 Dec;27(4):365-8. doi: 10.5625/lar.2011.27.4.365. Epub 2011 Dec 19. Lab Anim Res. 2011. PMID: 22232649 Free PMC article.

References

1. 1. Arch Ophthalmol. 1960 Dec;64:904-11 - PubMed
2. 1. J Pharmacol Exp Ther. 1969 Jan;165(1):14-22 - PubMed
3. 1. Proc Natl Acad Sci U S A. 1990 Jan;87(1):404-8 - PubMed
4. 1. Diabetes. 1992 Apr;41(4):552-6 - PubMed
5. 1. Diabetes. 1987 Jul;36(7):808-12 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Medical

  • MedlinePlus Health Information